Interim Report Q2 2026: Strong Sensor Sales and Improved Margins, Despite Continued U.S. Monitor Market Headwinds

Senzime reported Q2 2026 net sales of TSEK 24,671, down 4% YoY (US: TSEK 18,716, -6%; International: TSEK 5,955, +3%) and gross margin before depreciation rising to 65.7% from 61.8%. Losses narrowed but remained significant: operating profit before depreciation was TSEK -17,267 (vs -23,573) and EPS was SEK -0.14 (vs -0.24). Cash fell sharply to TSEK 37,112 from TSEK 132,162 as of June 30, indicating continued funding risk despite improving sensor sales momentum via TetraGraph utilization.

Analysis

The investable signal is not the modest gross-margin improvement; it is that the business is still too small to absorb fixed costs, yet the cash balance has already been cut to a level that implies refinancing pressure within the next 1-2 quarters. That makes the equity behave less like a growth story and more like a quasi-dilution call option: good unit economics can help, but only if they are scaling fast enough to outrun burn. At current run-rate sales, the company is nowhere near operating leverage, so incremental gross profit is being swallowed by the cost base.

The US weakness matters more than the headline suggests because that is likely the highest-value market for recurring sensor utilization. If the installed base really is expanding, the next proof point should show up first in recurring consumables attach rate, not just management language about momentum. Until then, the competitive read-through is that larger medtech and monitoring vendors with balance-sheet strength can win customer trust and procurement cycles simply by offering lower execution risk.

Contrarianly, the market may be underappreciating the quality of a rising utilization stream if TetraGraph is becoming a standard workflow item inside hospitals. But that thesis only works if system count and per-system consumption are accelerating, not merely stabilizing. The setup is falsified by either a funding solution that removes dilution risk for 12+ months, or a clear revenue inflection with materially lower quarterly cash burn; otherwise the stock likely stays pressured by financing overhang.

Key Decisions for Investors

• Short SNZZF on any post-print strength over the next 1-3 months; thesis is financing/dilution risk, not operating momentum. Cover if management secures non-dilutive funding or extends runway beyond 12 months.
• Pair trade: long IHI / short SNZZF for 3-6 months to isolate idiosyncratic microcap funding risk while keeping sector beta neutral.
• Set a hard alert on next quarter cash: if cash falls below ~20m SEK or operating burn does not improve meaningfully, increase conviction in the short; if sales reaccelerate and cash burn halves, step aside.
• Do not use options unless liquidity is confirmed; the cleaner expression here is common-stock short exposure because the main catalyst is a funding event, not a broad sector move.